Specialty Vaccine Company PaxVax Selected to Present at Cavendish Global Health Impact Forum

Redwood City, May 1, 2014 -- PaxVax Inc., a specialty vaccine company focused on travelers and biodefense markets with a social mission to ensure global access to its vaccines, today announced that company Chief Executive Officer Ken Kelley will present at the Cavendish Global Health Impact Forum taking place at the United Nations Headquarters and Rockefeller University in New York City, May 5-7, 2014.

Pages

Cholera

18.97
-72.29

Anthrax

40.71
-74.01

Typhoid

21.00
78.00

Hepatitis A

39.92
32.83

H5N1, Dengue

& HIV

-0.78
113.92

for protection wherever you are and wherever you go

PaxVax is a fully integrated specialty vaccine company committed to developing and commercializing innovative vaccines against infectious diseases.

PaxVax: Better Vaccines

37.44
-122.14
Subscribe to PaxVax - Socially Responsible Vaccines RSS